BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6. [PMID: 23298311 DOI: 10.1186/1741-7015-11-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Teama SH, Agwa SH, El Sayed OA, Sayed MM, Abd El Samee A, El Nakeep S. Assessment of interleukin-28B (interferon λ3) rs12979860 C/T gene polymorphism and the risk for hepatocellular carcinoma in chronic hepatitis C cirrhotic patients: . Egyptian Liver Journal 2016;6:48-53. [DOI: 10.1097/01.elx.0000515930.52529.6c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Kimble MM, Javanbakht M, Chew KW, Stafylis C, He D, Ramirez S, Baik Y, Saab S, Klausner JD. Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. BMC Infect Dis 2019;19:626. [PMID: 31307403 DOI: 10.1186/s12879-019-4223-9] [Reference Citation Analysis]
3 Shehab H, Elbaz T, Deraz D, Hafez A, Elattar I. The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res 2014;34:727-33. [PMID: 24730368 DOI: 10.1089/jir.2013.0127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Avanzi VM, Vicente BA, Beloto NCP, Gomes-da-Silva MM, Ribeiro CEL, Tuon FF, Vidal LRR, Nogueira MB, Raboni SM. Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil. Rev Soc Bras Med Trop 2017;50:470-7. [PMID: 28954067 DOI: 10.1590/0037-8682-0450-2016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
6 Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol 2014; 20(34): 12132-12143 [PMID: 25232248 DOI: 10.3748/wjg.v20.i34.12132] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
7 Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, Karimi Elizee P, Ghazimoghaddam M, Alavian SM. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016;16:e32703. [PMID: 27110259 DOI: 10.5812/hepatmon.32703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Bertol BC, Moreira S, Garcia RF, Ferreira LE, Debortoli G, Pinho Mde S, Amendola-Pires M, Maciel AM, Brandço-Mello CE, de França PH. IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. Front Microbiol 2015;6:153. [PMID: 25788894 DOI: 10.3389/fmicb.2015.00153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Kaczor MP, Seczyńska M, Szczeklik W, Sanak M. IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacol Rep 2015;67:260-6. [PMID: 25712648 DOI: 10.1016/j.pharep.2014.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int. 2014;34:890-895. [PMID: 24102823 DOI: 10.1111/liv.12321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
11 Jiménez-Sousa MA, Berenguer J, Fernández-Rodríguez A, Micheloud D, Guzmán-Fulgencio M, Miralles P, Pineda-Tenor D, García-Álvarez M, López JC, Aldámiz-Echevarria T, Carrero A, Resino S. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat 2014;21:189-97. [PMID: 24438680 DOI: 10.1111/jvh.12130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
12 Enache EL, Sin A, Enache LS, Bancu L. Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. J Mol Diagn 2017;19:857-69. [PMID: 28860020 DOI: 10.1016/j.jmoldx.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Ishikane M, Watanabe K, Tsukada K, Nozaki Y, Yanase M, Igari T, Masaki N, Kikuchi Y, Oka S, Gatanaga H. Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One 2014;9:e100517. [PMID: 24945812 DOI: 10.1371/journal.pone.0100517] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jiménez-Sousa MA, Berenguer J, Rallón N, Pineda-Tenor D, Aldamiz-Echevarria T, Soriano V, García-Álvarez M, Vazquez-Morón S, Restrepo C, Carrero A, Benito JM, Resino S. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver Int 2016;36:1258-66. [PMID: 26836972 DOI: 10.1111/liv.13079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Frias M, Rivero-Juárez A, López-López P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. Pharmacogenomics 2018;19:979-95. [PMID: 29992850 DOI: 10.2217/pgs-2018-0046] [Reference Citation Analysis]
16 Chen H, Zhang Y, Huang P, Xu Y, Wang J, Su J, Yu R. Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res 2014;28:476-83. [PMID: 25469117 DOI: 10.7555/JBR.28.20130142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ranjan P, Fletcher GJ, Radhakrishnan M, Sivakumar J, Premkumar PS, Goel A, Zachariah UG, Abraham P. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. Indian J Med Microbiol 2016;34:335-41. [PMID: 27514956 DOI: 10.4103/0255-0857.188329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Mansoor S, Riaz S, Kausar S, Muhammad Din S, Javed A, Sultan A, Mansoor A. Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? J Gen Virol 2016;97:2592-8. [PMID: 27498543 DOI: 10.1099/jgv.0.000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D, Dybowska D. Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Hepat Mon. 2013;13:e13678. [PMID: 24348648 DOI: 10.5812/hepatmon.13678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
20 Fouad H, El Raziky M, Hassan EM, Aziz GMA, Darweesh SK, Sayed AR. Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity. World J Hepatol 2016; 8(30): 1287-1294 [PMID: 27843539 DOI: 10.4254/wjh.v8.i30.1287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Durier N, Yunihastuti E, Ruxrungtham K, Kinh NV, Kamarulzaman A, Boettiger D, Widhani A, Avihingsanon A, Huy BV, Syed Omar SF, Sanityoso A, Chittmittrapap S, Dung NT, Pillai V, Suwan-Ampai T, Law M, Sohn AH, Matthews G. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. J Viral Hepat 2017;24:187-96. [PMID: 27917597 DOI: 10.1111/jvh.12630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
22 Forman MS, Valsamakis A. Hepatitis C Virus. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1599-616. [DOI: 10.1128/9781555817381.ch92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Karkhane M, Marzban A, Lashgarian HE, Zali MR; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Genetic Variations in Host Factors and their Critical Role on HCV Medication. Res Mol Med (RMM) 2017;5:6-16. [DOI: 10.29252/rmm.5.1.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Fernández-Rodríguez A, Berenguer J, Rallón N, Jiménez-Sousa MA, López JC, Soriano V, García-Álvarez M, Cosín J, Martínez P, Guzmán-Fulgencio M, Miralles P, Miguel Benito J, Resino S. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy. J Acquir Immune Defic Syndr 2014;67:113-9. [PMID: 25072612 DOI: 10.1097/QAI.0000000000000282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Fabrício-Silva GM, Poschetzky BS, de Mello Perez R, Dos Santos RC, Cavalini LT, Porto LC. Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil. Hepat Med 2015;7:71-9. [PMID: 26586969 DOI: 10.2147/HMER.S89447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Stiff A, Carson W III. Investigations of interferon-lambda for the treatment of cancer. J Innate Immun 2015;7:243-50. [PMID: 25661266 DOI: 10.1159/000370113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
27 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
28 Behera MK, Shukla SK, Dixit VK, Nath P, Abhilash VB, Asati PK, Jain AK. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian J Med Res 2018;148:200-6. [PMID: 30381543 DOI: 10.4103/ijmr.IJMR_1295_15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
29 Zhang L, Gwinn M, Hu DJ. Viral hepatitis C gets personal--the value of human genomics to public health. Public Health Genomics. 2013;16:192-197. [PMID: 23859951 DOI: 10.1159/000352014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Chayama K, Hayes CN. Interleukin-28B polymorphisms and hepatitis C virus clearance. Genome Med 2013;5:6. [PMID: 24533893 DOI: 10.1186/gm410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
31 Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol 2016;19:pyv135. [PMID: 26721949 DOI: 10.1093/ijnp/pyv135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
32 Xie X, Zhang L, Chen YZ. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis. Hum Immunol 2016;77:609-15. [PMID: 27180197 DOI: 10.1016/j.humimm.2016.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Jang ES, Ki M, Choi HY, Kim KA, Jeong SH; Korean hepatitis epidemiology study group. The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015. Hepatol Int 2019;13:599-608. [PMID: 31432446 DOI: 10.1007/s12072-019-09975-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Huang P, Wang CH, Zhuo LY, Xia XS, Yang S, Zhang JW, Fan HZ, Wu JJ, Yu R, Yue M, Zhang Y. Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations. Br J Biomed Sci 2020;77:112-7. [PMID: 32209020 DOI: 10.1080/09674845.2020.1747182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pineda-Tenor D, Jiménez-Sousa MA, Rallón N, Berenguer J, Soriano V, Aldámiz-Echevarria T, García-Álvarez M, Diez C, Fernández-Rodríguez A, Benito JM, Resino S. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Res Hum Retroviruses 2016;32:226-31. [PMID: 26499461 DOI: 10.1089/AID.2015.0223] [Reference Citation Analysis]
36 Kinkel HT, Karmacharya D, Shakya J, Manandhar S, Panthi S, Karmacharya P, Sitaula D, Thapaliya R, K C P, Rai A, Dixit S. Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal. PLoS One 2015;10:e0134455. [PMID: 26263394 DOI: 10.1371/journal.pone.0134455] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
37 Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 2017;206:165-74. [PMID: 28214926 DOI: 10.1007/s00430-017-0497-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
38 Veillon P, Fouchard-Hubert I, Larrey D, Dao MT, D'alteroche L, Boyer-Darrigand N, Picard N, Le Guillou-Guillemette H, Saulnier P, Ducancelle A, Loustaud-Ratti V, Lunel-Fabiani F. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C? J Interferon Cytokine Res 2016;36:204-14. [PMID: 26700738 DOI: 10.1089/jir.2015.0131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Domagalski K, Pawłowska M, Kozielewicz D, Dybowska D, Tretyn A, Halota W. The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. PLoS One 2015;10:e0130899. [PMID: 26115415 DOI: 10.1371/journal.pone.0130899] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Alvarez M, Aldámiz-Echevarria T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S. FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med 2014;12:198. [PMID: 25367448 DOI: 10.1186/s12916-014-0198-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
41 Liu C, Kao J. IL28B Genotype on HCV Infection in Asia. Curr Hepatitis Rep 2013;12:149-56. [DOI: 10.1007/s11901-013-0176-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Covolo L, Bibert S, Donato F, Bochud P, Lagging M, Negro F, Fattovich G. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 2014;39:322-30. [DOI: 10.1111/apt.12568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
43 Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaei M. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020;31:235-40. [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Guzmán-Fulgencio M, Rallón N, Berenguer J, Fernández-Rodríguez A, Soriano V, Miralles P, Jiménez-Sousa MA, Restrepo C, López JC, García-Álvarez M, Aldámiz T, Benito JM, Resino S. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients. HIV Med 2014;15:425-30. [PMID: 24580757 DOI: 10.1111/hiv.12126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Medrano LM, Rallón N, Berenguer J, Jiménez-Sousa MA, Soriano V, Aldámiz-Echevarria T, Fernández-Rodríguez A, García M, Tejerina F, Martínez I, Benito JM, Resino S. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients. J Transl Med 2016;14:257. [PMID: 27590274 DOI: 10.1186/s12967-016-1005-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
46 Harrison GL, Pryor J, Malani J, Supuri M, Masta A, Teriboriki B, Toatu T, Penny D, Allain JP, Barnes E, Pybus OG, Klenerman P. Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS One 2013;8:e66749. [PMID: 23976941 DOI: 10.1371/journal.pone.0066749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
47 Bello DD, Ita-nagy F, Hand J, Dieterich D. Treatment of hepatitis C in coinfected patients. Future Virology 2015;10:1291-305. [DOI: 10.2217/fvl.15.99] [Reference Citation Analysis]
48 Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Boyanova Y, Nikolova N, Romanciuc G, Dumitrascu D, Caloska-Ivanova V, Joksimovic N, Antonov K, Mateva L, Rostaing L, Dimovski A, Sikole A. Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 2015;15:55-9. [PMID: 26614853 DOI: 10.17305/bjbms.2015.632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
49 Kanwal F, White DL, Tavakoli-Tabasi S, Jiao L, Lin D, Ramsey DJ, Spiegelman A, Kuzniarek J, El-Serag HB. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol 2014;12:327-333.e1. [PMID: 23978349 DOI: 10.1016/j.cgh.2013.08.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis 2015; 5(4): 59-66 [DOI: 10.5495/wjcid.v5.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Zheng R, Zhao W, Dai D, Li C. Associations between MTHFR Ala222Val polymorphism and risks of hepatitis and hepatitis-related liver cancer: a meta-analysis. Tumor Biol 2014;35:1313-8. [DOI: 10.1007/s13277-013-1174-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat 2018;25:680-98. [PMID: 29345844 DOI: 10.1111/jvh.12866] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
53 Yang M, Rao HY, Feng B, Zhang W, Wei L. Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis. J Gastroenterol Hepatol 2013;28:1114-21. [PMID: 23611115 DOI: 10.1111/jgh.12233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
54 Yilmaz B, Çakmak Genç G, Karakaş Çelik S, Solak Tekin N, Can M, Dursun A. Association between Psoriasis Disease and IFN-λ Gene Polymorphisms. Immunol Invest 2022;:1-13. [PMID: 35118914 DOI: 10.1080/08820139.2022.2036187] [Reference Citation Analysis]
55 El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19(44): 7880-7888 [PMID: 24307782 DOI: 10.3748/wjg.v19.i44.7880] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
56 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
57 Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One 2014;9:e112592. [PMID: 25393304 DOI: 10.1371/journal.pone.0112592] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
58 Lee T, Tillmann HL, Patel K. Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. Mol Diagn Ther 2014;18:25-38. [DOI: 10.1007/s40291-013-0053-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. Journal of Hepatology 2014;61:957-61. [DOI: 10.1016/j.jhep.2014.06.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
60 Miri HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, Kabelitz D, Kalantar K. Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. Arch Virol 2021;166:2469-78. [PMID: 34216268 DOI: 10.1007/s00705-021-05141-8] [Reference Citation Analysis]
61 Haj-sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 2015; 21(29): 8935-8942 [PMID: 26269684 DOI: 10.3748/wjg.v21.i29.8935] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
62 Guzmán-Fulgencio M, Berenguer J, Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosín J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013;27:1231-8. [PMID: 23811951 DOI: 10.1097/QAD.0b013e32835f5b9c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol 2016;31:1628-37. [PMID: 26990023 DOI: 10.1111/jgh.13341] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
64 Pérez-García F, Jiménez-Sousa MÁ, Soria S, Jorge-Monjas P, Fernández-Rodríguez A, Gómez-Sánchez E, Heredia-Rodríguez M, Gómez-Pesquera E, Martínez-Paz P, Tamayo E, Resino S. IFNL3 rs12980275 Polymorphism Predicts Septic Shock-Related Death in Patients Undergoing Major Surgery: A Retrospective Study. Front Med (Lausanne) 2020;7:186. [PMID: 32478085 DOI: 10.3389/fmed.2020.00186] [Reference Citation Analysis]
65 Enache EL, Sin A, Bancu L, Ramière C, Diaz O, André P, Enache LS. Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. Int J Mol Sci 2015;16:22223-42. [PMID: 26389885 DOI: 10.3390/ijms160922223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
66 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
67 Jiménez-Sousa MA, Rallón N, Berenguer J, Pineda-Tenor D, López JC, Soriano V, Guzmán-Fulgencio M, Cosín J, Retana D, García-Álvarez M, Miralles P, Benito JM, Resino S. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. J Clin Virol 2015;65:62-7. [PMID: 25766991 DOI: 10.1016/j.jcv.2015.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]